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Abstract
Motivation: Timely identification of Mycobacterium tuberculosis (MTB) resistance to existing
drugs is vital to decrease mortality and prevent the amplification of existing antibiotic resistance.
Machine learning methods have been widely applied for timely predicting resistance of MTB given
a specific drug and identifying resistance markers. However, they have been not validated on a
large cohort of MTB samples from multi-centers across the world in terms of resistance prediction
and resistance marker identification. Several machine learning classifiers and linear dimension re-
duction techniques were developed and compared for a cohort of 13 402 isolates collected from 16
countries across 6 continents and tested 11 drugs.
Results: Compared to conventional molecular diagnostic test, area under curve of the best machine
learning classifier increased for all drugs especially by 23.11%, 15.22% and 10.14% for pyrazinamide,
ciprofloxacin and ofloxacin, respectively (P< 0.01). Logistic regression and gradient tree boosting found
to perform better than other techniques. Moreover, logistic regression/gradient tree boosting with a
sparse principal component analysis/non-negative matrix factorization step compared with the classifier
alone enhanced the best performance in terms of F1-score by 12.54%, 4.61%, 7.45% and 9.58% for ami-
kacin, moxifloxacin, ofloxacin and capreomycin, respectively, as well increasing area under curve for
amikacin and capreomycin. Results provided a comprehensive comparison of various techniques and
confirmed the application of machine learning for better prediction of the large diverse tuberculosis data.
Furthermore, mutation ranking showed the possibility of finding new resistance/susceptible markers.
Availability and implementation: The source code can be found at http://www.robots.ox.ac.uk/
davidc/code.php
Contact: yang.yang@eng.ox.ac.uk
Supplementary information: Supplementary data are available at Bioinformatics online.
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1 Introduction
Tuberculosis (TB) is one of the leading causes of mortality across the
world (World Health Organization et al., 2016). In 2016, there
were 600 000 new cases with resistance to rifampicin (RIF), the
most effective first-line drug, including 490 000 cases of multi-drug-
resistant TB (MDR-TB) (World Health Organization et al., 2016).
Hence, TB drug resistance is an urgent public health concern in the
field of infectious disease. In TB, drugs are usually grouped into
first-line drugs [isoniazid (INH), RIF, ethambutol (EMB) and pyra-
zinamide (PZA)] and second line drugs [streptomycin (SM),
fluoroquinolones-ofloxacin (OFX), moxifloxacin (MOX), cipro-
floxacin (CIP), kanamycin (KAN), amikacin (AK) and capreomycin
(CAP)] (Jnawali and Ryoo, 2013). Conventional whole genome
sequencing (WGS) methods are based on identifying a number of
variants (i.e. single nucleotide polymorphisms, insertions or dele-
tions) and interpreting them as associated (or not) with conferring
resistance to each individual drug (Schleusener et al., 2017). Hence,
they relies on a library of previously identified resistance-associated
variants (Coll et al., 2015; Georghiou et al., 2012; Walker et al.,
2015). Such techniques can result in lower performance particularly
for less-studied drugs e.g. PZA and second-line drugs due to high
dimensionality and improper composition of the library.
In addition to methods based on known mutations, machine learn-
ing models have been applied to determine drug resistance, e.g. logistic
regression (LR), support vector machine (SVM) and random forest
(RF) (Farhat et al., 2016; Yang et al., 2018; Zhang et al., 2013). Such
models have been shown to perform similarly to the variant-based as-
sociation rules for well-studied drugs, e.g. INH, RIF and EMB while
outperforming them for less-studied drugs, e.g. PZA. However, to date
few studies have investigated machine learning methods for TB resist-
ance prediction and they have used a limited number of isolates.
Zhang et al. (Zhang et al., 2013) used LR to investigate 161 isolates
from China to try to discover new genes associated with resistance to
seven drugs. Yang et al. (Yang et al., 2018) considered 1839 UK bac-
terial isolates and compared a number of classification models for eight
drugs (CAP, AK and KAN excluded from their analysis due to insuffi-
cient resistant samples). Farhat et al. (Farhat et al., 2016) used a more
geographically diverse dataset to investigate the performance of RF
using 1397 isolates. Considering a small dataset from a limited com-
munity can lead to over-fitted models. Although considering cross-
validation and regularization terms can help with over-fitting, a larger
more diverse dataset should be considered to confirm the performance
of them for resistance prediction and also have a more general trained
model that can better predict the future samples. In addition, as the fea-
ture space dimensionality grows, it becomes sparser and sparser (as the
high dimensional genomic information from WGS). Consequently, fit-
ting a separable hyperplane can be easier but the classifier then tries to
learn the specific instances and outliers of the training dataset. It then
could fail to perform well for the unseen data. Furthermore, dimension
reduction techniques can be used to reduce the curse of dimensionality,
noise and improve the computational cost.
Here, our aim is to confirm the application of machine learning
methods considering a more general dataset and also to check the ef-
fect of reducing the dimension on final results. Hence, as an exten-
sion of previous work, a number of machine learning models were
developed and evaluated for resistance prediction. We studied a data-
base of 13 402 isolates that is a more diverse and much larger dataset
compared to reported machine learning TB studies. Similar to previ-
ous work, this dataset has some missing data and more susceptible
isolates than resistant ones (in particular, being highly imbalanced
for some drugs i.e. CAP and AK). Moreover, some other ensemble
learning techniques were developed and compared with the basic ma-
chine learning and RF models mainly used in other studies (Farhat
et al., 2016; Yang et al., 2018; Zhang et al., 2013). These methods
were considered here as they have been shown to be accurate and ef-
fective classification models in several applications in other areas
(Ehrentraut et al., 2016; Li et al., 2018). Moreover, they reduce the
variance by considering several independent/sequentially-built learn-
ers that are especially useful for the complex dataset in this study.
Subsequently, highly ranked features from the top performing classi-
fiers were represented and compared with the library of known
mutations. The effect of two linear dimension reduction techniques
on performance was also investigated especially for less-studied drugs
in which not all resistance-associated mutations are known. As a
summary, our results confirm the application of machine learning
algorithms to drug resistance prediction for the diverse TB dataset
considered here. Moreover, results show that ranked variants include
known resistance/susceptible markers, resistance co-occurrence, lin-
eage associated mutations and unknown mutations possibly as new
resistance/susceptible markers.
2 Materials and methods
2.1 WGS and drug susceptibility test
For details of DNA sequencing refer to the work presented by
(CRyPTIC Consortium and the 100 000 Genomes Project, 2018) and
(Walker et al., 2015). Sequenced reads were aligned to the reference
Mycobacterium tuberculosis (MTB) strain. Then nucleotide bases
were filtered based on the sequencing and alignment quality and per
base coverage. Hence, low confident nucleotide bases were denoted as
null calls and not considered in our analysis. We had several ways to
treat a null call in an isolate: (i) remove the sample completely from
the analysis which drastically reduce the sample size (34% of isolates
have one or more null calls in the genetic regions of interest) and
generalizability, (ii) consider the null calls as no variant (i.e. 0) which
is a conservative option and means that performance will be an under-
estimate of true performance if all variants known and (iii) consider
null values as missing and impute their values, either singly or multi-
ply. We chose the second option (assume absence of variant) because
the total number of positions across the genetic regions of interest
(5919 positions) across all isolates (13 402) with null calls were very
small [150958/79326438(¼591913402) (0.19%)] and because of
the complexity of multiple imputation models based on the 5919 posi-
tions. (ii) Is effectively a single hard (conservative) imputation. On all
isolates, drug susceptibility testing was performed for up to 11 drugs
through an initial phenotypic drug susceptibility testing using culture
and confirmed using Lowenstein Jensen methods.
2.2 Baseline methods
Existing baseline methods classify drug resistance as present or absent
based on a number of predetermined library of variants from the lit-
erature. The method denoted direct association (DA) uses an ‘OR’
rule to classify an isolate against a given drug: the isolate is labelled as
resistant if any of its mutations is a resistant variants. Otherwise, it is
classified as susceptible if only susceptible variants exist in the isolate.
The library described by Walker et al. in 2015 (Walker et al., 2015)
was used throughout the classification comparison.
2.3 Linear dimension reduction
Dimensionality reduction plays an important role in machine learning
mainly for a dataset with thousands of features, such as the TB data.
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Moreover, they have been shown to improve classification performance
in many applications by reducing unimportant and redundant features
(Benetos et al., 2006; Malhi and Gao, 2004). Principal components ana-
lysis (PCA) as a common linear dimensionality reduction technique, is
easy to understand and use in real applications and also helps to improve
the classification results. It projects the data into a lower dimensional
space using singular value decomposition (SVD), X ¼ URVT where U
and V are singular vectors and R represents singular values (Eckart and
Young, 1936; Golub and Van Loan, 2012). Input to SVD can have
mixed-signs and there is no constraint on the factors’ signs. Non-
negative matrix factorization (NMF) restricts factors to be non-negative
and can be used when the input data is non-negative. Hence, it works
based on putting a non-negativity constraint on the extracted compo-
nents, Xþ ¼WþHþ where ð:Þþ represents the non-negativity of all ele-
ments of the input data and also components. Binary matrix
factorization is another extension of NMF for the binary data by con-
straining components to be binary, X01 ¼W01H01 where ð:Þ01
represents the binary elements. Sparsity constraints (by constraining
factorized components’ norm) can be added to the optimization of PCA
and NMF to enhance interoperability and stability of components
(SPCA/SNMF) (Hoyer, 2004; Zou et al., 2006). Sparsity constraints are
particularly important for our data due its sparse nature. Here, our
results focus on linear techniques; as adding the binary constraint did not
improve our results Supplementary Material I, only SPCA and SNMF
were reported. A total of 100 components were kept as experiments
show that 100 components keep the maximum variance for all drugs.
2.4 Classification methods
We investigated three basic machine learning classifiers; SVM, LR
and product-of-marginals (PM), based on the original feature space or
the feature space after dimension reduction. Three ensemble learning
methods, RF, Adaboost and gradient tree boosting (GBT) were also
considered. Details of each method, parameter settings and pros and
cons of each method are shown in Supplementary Material A.
3 Results
3.1 Data description
The dataset used in this paper contains 13 402 isolates collected from
across the world. Twenty-three genes which contain previously-found re-
sistance-associated variants (Walker et al., 2015) were targeted. For each
isolate, the presence/absence of a mutation was represented by a binary
variable, with 1 indicating the presence and 0 indicating the absence. The
mean of variants per isolate was 14, ranging between 1 and 132. In total,
5919 variants were found in the 23 candidate genes across the isolates.
Hence, a binary vector of 5919 was formed and considered fully or par-
tially for the feature space (3.2 Feature spaces). For each drug and isolate,
a binary label of resistance/susceptible was considered. The phenotypic in-
formation was available for up to 11 anti-TB drugs as shown in Table 1
(not all samples were tested against all drugs, leading to missing labels).
Around 98% of isolates were tested for phenotypic resistance to
INH and RIF, 96% for EMB, 81% for PZA, 52% for SM, less than a
quarter for OFX, CAP, AK, KAN and MOX and only 4% for CIP
showing more missing labels for second-line drugs. All 11 drugs had
substantially more susceptible than resistant isolates; more than 87%
of isolates were susceptible for EMB and PZA and 72% for INH and
RIF, leading to a highly imbalanced dataset. Moreover, resistance to
some drugs commonly co-occurred with others, as expected, e.g. 715
isolates were co-resistant to INH, PZA, RIF and EMB.
3.2 Feature spaces
Following the work presented by (Yang et al., 2018) and to evaluate
the performance of the different classifiers, three feature sets were
considered: (i) F1 was the baseline feature space is all variants found
within the 23 candidate genes, (ii) F2 was the predetermined
resistance-associated variants as listed in (Walker et al., 2015)
(Supplementary Material G) and (iii) F3 was a subset of F1 including
only resistance-associated genes for the particular drug [genes with
resistance-determinants specific to each drug can be found at
(Walker et al., 2015)].
3.3 Training and testing
For all experiments, the classification was performed by training a
balanced training dataset and then tested over an imbalanced dataset.
This was run over 100 iterations of 5-fold cross validation. In each
fold, 20% of the data was considered as the test set. Within the
remaining 80% of the data, susceptible samples were sub-sampled
randomly to make the number of resistant and susceptible samples
equal (i.e. create a balanced set) and then split 80:20 into training and
validation sets. The performance in terms of accuracy, sensitivity, spe-
cificity, F1-score and area under curve (AUC) was calculated for the
validation sets (for parameter setting) and test sets (for final compari-
son) and averaged over iterations; mean and SD were reported.
Accuracy ¼ TPþ TN
TPþ TNþ FPþ FN
Sensitivity ¼ TP








where TP, TN, FP and FN are true positive, true negative, false pos-
itive and false negative, respectively. Considering a probability esti-
mate as the output of each classifier for the validation set and setting
various thresholds to categorize this output as resistant/susceptible
could result in different TP, FP, FN and TN rates. Alternatively, a
receiver operating characteristic (ROC) curve showing the sensitiv-
ity as a function of 1–specificity for different thresholds; each point
in the curve indicates a specific value for sensitivity, specificity and
accuracy. AUC is the area under the ROC curve. Here, the ‘internal’
cross-validation on the 80% training dataset was used to select a de-
cision threshold that maximizes the accuracy. The parameters of the
models (kernel parameters for SVM or number of ensembles for RF)
were also optimized through the internal cross-validation on the
train data. This was done by a grid search over a range of values and
Table 1. The phenotype profile; the number of isolates that are resistant or susceptible
Drug INH EMB RIF PZA SM KAN AK CAP CIP OFX MOX
Susceptible 9620 11 322 10 359 9806 5105 1925 2690 2741 529 2618 1249
Resistant 3457 1571 2808 1262 1729 242 273 315 77 458 262
Total tested 13 077 12 893 13 167 11 068 6834 2167 2963 3056 606 3076 1511
Missing 325 509 235 2334 6568 11 235 10 439 10 346 12 796 10 326 11 891
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selecting parameters that generated the best AUC. The workflow of
examined classifiers can be seen in Supplementary Material F.
3.4 Classification results
Figure 1 compares machine learning techniques in terms of AUC
considering F1 for 11 drugs (Supplementary Material C for F1-F3).
Different classifiers led to similar AUC performances except for
(F1þPM) for INH, SM, AK, MOX, OFX and KAN. AUC was
much higher for PZA, MOX, OFX considering F1 compared to F2-
F3, e.g. 93.89% considering F1 for PZA compared to 69.59% and
88.69% considering F2-F3 for the same drug.
Figure 2 provides AUC considering (F1þ SPCA/SNMF); 100
components were considered here for all drugs. Considering SNMF
led to the best performing model for INH, EMB, RIF, PZA, SM
(with GBT for classification) while SPCA for AK, CAP (with LR-L2
for classification), MOX, OFX, CIP (with GBT for classification)
and KAN (with RF for classification). (F1þ SNMFþPM) was per-
formed better for RIF, SM and CAP and (F1þ SPCAþPM) for PZA
and AK in comparison with (F1þ SNMFþLR-L2). With SNMF,
only ensemble methods had the highest AUC for AK, MOX, OFX
and KAN while with SPCA only (F1þ SPCAþPM/LR-L1) did not
perform well for them. Overall, (F1þ SPCA/SNMFþGBT) was the
top performing model for most drugs in terms of AUC (Fig. 2).
Table 2 provides a comparison of DA and the best performing model
obtained by applying machine learning techniques on test sets considering
F1–F3 for 11 drugs. Compared to DA, considering F1 with or without a
dimension reduction stage improved AUC and sensitivity for all drugs,
significantly (Wilcoxon signed-rank P<0.01). The AUC especially
increased by 23.11% for PZA, 15.22% for CIP, over 8.68% for AK,
MOX, OFX and CAP and 5.16% for EMB, SM and KAN. Sensitivity
increased by 44.29% for PZA, 30.42% for CIP, more than 12% for AK,
MOX and OFX, 8% for EMB and KAN and 4% for SM and CAP.
Details of comparison of all methods, drugs and features can be
found in Supplementary Material B. In general, using F1 improved sen-
sitivity and AUC while specificity was lower than DA. Classification
on the reduced dimension (SNMF/SPCAþF1) compared to F1 resulted
in better AUC for AK and CAP and similar AUC for other drugs
(Supplementary Material B). Similarly, the sensitivity increased slightly
for EMB, PZA, MOX, INH and SM using dimension reduction.
F1-Score is also reported and compared with DA. The best
model based on integrating dimension reduction with the classifica-
tion stage improved the F1-Score more than 9% for PZA, CAP and
CIP and 7% for KAN compared to considering whole F1. More
details can be found in Supplementary Material C.
3.5 Mutation ranking
Table 3 shows the top 10 important features selected for each drug by
considering the top performing models (Supplementary Material D
shows the mutation for LR-L1, LR-L2 and GBT models). Mutations
that were associated with resistance to the specific drug in the





















Fig. 1. Classification performance (AUC%) considering six machine learning classifiers (LR with L1 and L2 regularization terms, SVM with Linear and RBF kernels,
RF, Adaboost, PM and GBT) across 11 anti-TB drugs and F1 feature space


































Fig. 2. Classification performance (AUC%) considering six machine learning classifiers across 11 anti-TB drugs with (a) SNMF-F1 and (b) SPCA-F1
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library are indicated in boldface. Results indicated that machine
learning methods could also rank several known mutations as
important especially for well-studied drugs. There are also some lin-
eage defining mutations ranked as important for AK, OFX, KAN,
CAP and CIP (indicated by  in Table 3). However, there were sev-
eral mutations selected as important that were not in the library and
not lineage defining some with gene related to each considered drug
(for EMB, PZA, SM, AK, OFX, MOX and CAP indicated by o in
Table 3). Moreover, there was high overlap between selected muta-
tions based on all three methods for RIF, OFX and MOX, LR-L1
and LR-L2 for EMB and KAN and LR-L2 and GBT for INH and
EMB. Furthermore, some mutations found to be important for more
than one drug.
4 Discussion
Developing machine learning techniques is especially important to im-
prove TB resistance prediction, mainly sensitivity for less-studied drugs.
Table 2 and Supplementary Material B indicate that machine learning
techniques generally improved AUC and sensitivity but resulted in
lower specificity compared to a clinical algorithm (DA). This is because
machine learning techniques can tune the optimal operational point to
balance sensitivity and specificity, while DA cannot. The performance
is especially improved for less-studied drugs, e.g. for PZA, the 2015
DA method resulted in relatively low sensitivity (43.14%), AUC
(70.78%) and F1-Score (55.55%) which was improved by using
(F1þLR-L2) to 88.12%, 93.89% and 64.36%, respectively. The
results indicate the effectiveness of machine learning methods is based
on the input feature space. There may be several reasons for this
including the existence of additional resistance-associated mutations to
the ones reported in the literature or co-occurrence of resistance to
multiple drugs within the 23 genes considered in this paper.
However, mutations within known genes contributed more to
identify resistance to each drug. Hence, F3 feature set contains
enough information to solve the classification performance in terms
of F1-Score (Supplementary Material B and C). On other hand, F1
feature space resulted in higher AUC and sensitivity but lower speci-
ficity (Supplementary Material B). It could be that there are some
resistance-related variants and interactions from not only genes sus-
pected to be related to resistance of each drug, but also the remain-
ing of the 23 genes. Lower specificity means more susceptible
isolates were falsely classified to be resistant possibly due to the re-
sistance co-occurrence pattern dominating the classification. The
lower performance for CAP, MOX, AK and CIP (although still high-
ly improved in comparison with DA) is mainly because there were
very few labelled isolates especially resistant cases for them. It could
be also due to the underlying resistance co-occurrence pattern.
In comparison with the former work published by (Yang et al.,
2018) that showed higher AUC using F1–F3 depending on the drug,
our results showed that F1 had better AUC. It can mainly be due to
more cases of resistance co-occurrence, existence of additional muta-
tions to reported resistance-determinants or complex interaction of
mutations for our more complex dataset. It also shows the potential of
using machine learning to work directly with high dimensional WGS.
Moreover, reported AUC in their work was higher for eight reported
drugs except for SM compared to our reported results (Supplementary
Material K) potentially as a result of considering a larger more complex
dataset here and lack of generalizability of the resistance co-occurrence
predictions. Moreover, LR-L1 was not among the top performing clas-
sifiers and GBT was not considered in their analysis, whereas they were
top performing methods especially considering F1 for our data. One
possible reason could be the diversity of the data that was available for
the training stage in our data. As a result, it could lead to less over-
fitting and a more generalizable conclusion. Furthermore, LR can work
well with binary target, usually has low variance and is less prone to
over-fitting by using regularization terms. GBT is an accurate and effect-
ive classification model in several applications and is robust to outliers
in the output space by considering a robust loss function. Consequently,
both methods could work for this complex and noisy dataset. In add-
ition, only RF was considered by (Farhat et al., 2016) for 13 drugs.
Considering drugs analyzed in both papers, we had better sensitivity for
EMB, PZA, SM, KAN, CAP and CIP and higher or similar specificity
for INH, EMB and OFX (Supplementary Material K).
Regarding mutations ranking, machine learning methods ranked
not only the known mutations as important but also some other
mutations in genes associated with resistance to other drugs. It can
be because that there are some commonly extracted mutations for
some drugs due to several cases of MDR-TB and hence a limitation
of the feature ranking based on the single-label drug resistance clas-
sification. It also can reflect known accumulation of drug resistance
mutations as patients take second-line drugs after first-line drugs.
Moreover, there are some mutations for some drugs that are not in
the library as associated to that drug, are not in the list of lineage
defining mutations and have genes known to be associated to that
drug. Hence, they can be considered as drug-associated mutations
found by machine learning methods. Consequently, it shows the
Table 2. Comparing the best machine learning classifier and DA considering 11 drugs
Drugs DA Best method
Sensitivity Specificity AUC Feature setþClassifier Sensitivity Specificity AUC
INH 91.9561.04 98.716 0.22 94.956 0.54 F1þLR – L2 92.19^6 0.94 98.386 0.29 97.89^6 0.38
EMB 83.3161.62 95.176 0.38 89.246 0.85 F1þLR – L2 92.12^6 0.98 91.896 0.84 96.25^6 0.54
RIF 91.7061.19 98.736 0.22 95.226 0.59 F1þLR – L2 92.27^6 1.25 97.456 0.63 98.08^6 0.32
PZA 43.1162.97 98.466 0.27 70.786 1.46 F1þLR – L2 88.12^6 2.65 88.916 1.66 93.89^6 0.80
SM 82.8061.90 97.196 0.44 89.996 0.99 F1þLR – L2 87.40^6 1.98 94.156 1.23 95.15^6 0.56
AK 65.2165.32 99.706 0.24 82.466 2.70 F1þ SPCAþLR – L2 77.23^6 6.96 89.846 3.05 91.37^6 2.36
MOX 62.9766.60 98.806 0.68 80.896 3.32 F1þGBT 76.84^6 9.29 87.196 8.21 90.27^6 2.96
OFX 65.0763.92 99.316 0.28 82.196 1.98 F1þGBT 79.06^6 6.94 90.886 6.38 92.33^6 1.49
KAN 72.3165.40 97.616 0.65 84.966 2.68 F1þLR – L2 80.41^6 6.48 93.486 4.93 92.49^6 2.93
CAP 59.6865.84 93.876 0.88 76.786 2.96 F1þ SPCAþLR – L2 64.44^6 6.02 92.746 2.52 85.46^6 2.02
CIP 46.65610.10 99.246 0.89 72.956 5.17 F1þLR – L2 79.86^6 9.98 85.376 7.65 89.53^6 4.06
Note: Sensitivity, specificity and AUC (mean6 standard error) is reported. Wilcoxon signed-rank test was used to calculate the P-value of each method com-
pared with the DA and ^ indicate s P< 0.01.
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application of machine learning to find new important mutations.
We note if there are some highly correlated features, any of them
may be selected with no preference of one over others. After select-
ing one of such a set of highly correlated features, the importance of
other correlated features is decreased. From the point of view of
classification, this is actually useful as it removes the features
described by others. However, for feature selection it may lead to a
conclusion that one feature is important in comparison to others
while in fact they are all highly correlated. Moreover, the ranked lin-
eage associated mutations e.g. rpob_C-61T appeared in lineages
with a large number of isolates such as Central Asian sub-lineage.
Therefore, the classifier may select them as important as they may
improve the classification for a large number of isolates. Hence,
ranking them as important could be due to limitations of machine
learning based feature selection (due to points explained above).
SPCA/SNMF can avoid the curse of dimensionality while keeping
most variance in the data, hence leading to similar or higher perform-
ance (up to 1%, Supplementary Material H). Here, results considering
100 components were reported for all drugs (check Supplementary
Material J for 50 and 150 components). We found that the dimension
reduction step improved the performance of ensemble methods espe-
cially GBT for AK, MOX, OFX and KAN drugs while basic machine
learning methods could not perform well for them. The trees cannot
sum the effect of multiple variables and work considering one variable
at a time. They run out of data instances before taking all necessary
variables into account. Hence, SPCA/SNMF and similar methods can
be helpful since they aggregate the information from multiple varia-
bles. Dimensionality reduction can also serve as regularization in
order to prevent over-fitting. In addition, for less studied drugs the
available catalog of resistance-associated mutations has not been
studied completely. Hence, considering all available variants and
allowing machine learning methods to reduce the dimension can im-
prove the performance as seen in our results for CAP and AK. In
terms of computational cost, all dimension reduction stages impose
some time complexity to factorize the data. If we note n as the num-
ber of isolates and m as the number of features (variants),
tmax ¼ maxðm; nÞ, and tmin ¼ minðm;nÞ, then the time complexity of
PCA is O(tmax2tmin) and SPCA is O(mnk) for extracting top K com-
ponents. Similar time complexity can also be seen for NMF and
SNMF. However, this time will be compensated later by passing
fewer features to the classifiers to learn the susceptibility/resistance.
Here, we did not optimize the number of SPCA/SNMF components
for each drug as the feature space (eigen vectors). Optimizing the
number of components could improve the performance for each drug
further. However, such techniques have a limitation that they cannot
be used for feature selection/mutation identification.
Finally, we note that there are several limitations regarding our
analysis including the error in phenotypes, assumption of resistance in-
dependence for each drug (labels learned independently), independence
of feature space for classification, considering all variants to have the
same importance, ignoring missing labels and considering null calls in
an isolate as no variant. Moreover, there might be some lineage related
mutations as well as frequently appeared mutations ranking as import-
ant. LR-L2 (without the dimension reduction stage) or GBT (by adding
it) could be two possible classifiers to be considered in the real practice
or for the study of any drugs that was not reported here.
5 Conclusion
Several machine learning classifiers were investigated for TB resist-
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classification of resistance from genetic data and show potential in
the analysis of a large dataset with high dimensionality. Three feature
spaces were considered, in which F1/SPCA-F1 for AUC and sensitivity
and F3 for F1-score were more informative. The best performing clas-
sifier outperformed the assessed DA method in terms of F1-Score,
AUC and sensitivity. We also showed the dimension reduction step
can improve the performance of resistance classification for some
drugs. Consequently, this work shows that machine learning methods
can perform well considering a large number of isolates and genetic
variations and results are more promising for less studied drugs.
Analyzing importance of variants using machine learning techniques
also shows the possibility of finding new drug-associated mutations.
Considering the whole genome sequences including positions outside
23 genes and deep networks for non-linear classification and dimen-
sion reduction and also optimizing the number of SPCA/SNMF com-
ponents can be considered as the future work.
Members of the CRyPTIC consortium
Derrick W Crook, Timothy EA Peto, A Sarah Walker, Sarah J
Hoosdally, Ana L Gibertoni Cruz, Joshua Carter, Clara Grazian,
Samaneh Kouchaki, Yang Yang, Timothy M Walker, Philip W
Fowler, Daniel Wilson and David A Clifton, University of Oxford;
Zamin Iqbal and Martin Hunt, European Bioinformatics Institute; E
Grace Smith, Priti Rathod, Lisa Jarrett and Daniela Matias, Public
Health England, Birmingham; Daniela M Cirillo, Emanuele Borroni,
Simone Battaglia, Arash Ghodousi, Andrea Spitaleri and Andrea
Cabibbe, Emerging Bacterial Pathogens Unit, IRCCS San Raffaele
Scientific Institute, Milan; Sabira Tahseen, National Tuberculosis
Control Program Pakistan, Islamabad; Kayzad Nilgiriwala and
Sanchi Shah, The Foundation for Medical Research, Mumbai;
Camilla Rodrigues, Priti Kambli, Utkarsha Surve and Rukhsar Khot,
P.D. Hinduja National Hospital and Medical Research Centre,
Mumbai; Stefan Niemann, Thomas Kohl and Matthias Merker,
Research Center Borstel; Harald Hoffmann, Nikolay Molodtsov and
Sara Plesnik, Institute of Microbiology & Laboratory Medicine, IML
red, Gauting; Nazir Ismail, Shaheed Vally Omar, Lavania Joseph and
Elliott Marubini, National Institute for Communicable Diseases,
Johannesburg; Guy Thwaites, Thuong Nguyen Thuy Thuong, Nhung
Hoang Ngoc and Vijay Srinivasan, Oxford University Clinical
Research Unit, Ho Chi Minh City; David Moore, Jorge Coronel and
Walter Solano, London School of Hygiene and Tropical Medicine
and Universidad Peruana Cayetano Hereda´, Lima; George F Gao,
Guangxue He, Yanlin Zhao, Aijing Ma and Chunfa Liu, China CDC,
Beijing; Baoli Zhu, Institute of Microbiology, CAS, Beijing; Ian
Laurenson and Pauline Claxton, Scottish Mycobacteria Reference
Laboratory, Edinburgh; Robert J Wilkinson, University of Cape
Town; Ajit Lalvani, Imperial College London; James Posey, CDC
Atlanta; Jennifer Gardy, University of British Columbia; Jim
Werngren, Public Health Agency of Sweden; Nicholas Paton,
National University of Singapore; Ruwen Jou, Mei-Hua Wu, Wan-
Hsuan Lin, CDC Taiwan; Lucilaine Ferrazoli, Rosaline Siqueira de
Oliveira, Institute Adolfo Lutz, Sao Paolo. Authors contributing to
the CRyPTIC consortium are (in alphabetical order): Irena
Arandjelovic, I~naki Comas, Francis Drobniewski, Qian Gao, Vitali
Sintchenko, Philip Supply and Dick van Soolingen.
Acknowledgements
Y.Y. thanks support of Oxford Suzhou Centre for Advanced Research.
D.W.C., S.K., T.E.A.P., A.S.W., T.M.W., Y.Y. and D.A.C. contributed
towards study design; S.K., Y.Y. and D.A.C. contributed towards data ana-
lysis; S.K. wrote the manuscript with comments from Y.Y., A.S.W.,
T.M.W., D.J.W. and D.A.C.; all authors contributed feedback on the
manuscript.
Funding
The work was supported by the National Institute for Health Research
(NIHR) Oxford Biomedical Research Centre; the CRyPTIC consortium
which is funded by a Wellcome Trust/Newton Fund-MRC Collaborative
Award [200205/Z/15/Z] and the Bill and Melinda Gates Foundation Trust
[OPP1133541]. D.J.W. is a Sir Henry Dale Fellow, jointly funded by the
Wellcome Trust and the Royal Society [101237/Z/13/Z]. SK was also sup-
ported by EPSRC (Grant EP/N020774/1).
Conflict of Interest: none declared.
References
Benetos,E. et al. (2006) Applying supervised classifiers based on non-negative
matrix factorization to musical instrument classification. In: 2006 IEEE
International Conference on Multimedia and Expo, IEEE, Toronto,
Ontario, Canada, pp. 2105–2108.
Coll,F. et al. (2015) Rapid determination of anti-tuberculosis drug resistance
from whole-genome sequences. GenomeMed., 7, 1–10.
CRyPTIC Consortium and the 100 000 Genomes Project. (2018) Prediction of sus-
ceptibility to first-line tuberculosis drugs by DNA sequencing. N. Engl. J. Med,
379, 1403–1415.
Eckart,C. and Young,G. (1936) The approximation of one matrix by another
of lower rank. Psychometrika, 1, 211–218.
Ehrentraut,C. et al. (2016) Detecting hospital-acquired infections: a document
classification approach using support vector machines and gradient tree
boosting. Health Inform. J., 24, 24–42.
Farhat,M.R. et al. (2016) Genetic determinants of drug resistance in
Mycobacterium tuberculosis and their diagnostic value. Am. J. Resp. Crit.
Care Med., 194, 621–630.
Georghiou,S.B. et al. (2012) Evaluation of genetic mutations associated with
Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreo-
mycin: a systematic review. PLoS One, 7, 1–12.
Golub,G.H. and Van Loan,C.F. (2012)Matrix Computations. Vol. 3. JHU Press.
Hoyer,P.O. (2004) Non-negative matrix factorization with sparseness con-
straints. J. Mach. Learn. Res., 5, 1457–1469.
Jnawali,H.N. and Ryoo,S. (2013) First- and second-line drugs and drug resist-
ance. In: Tuberculosis-Current Issues in Diagnosis andManagement. InTech.
Kandler,J.L. et al. (2018) Validation of novel Mycobacterium tuberculosis iso-
niazid resistance mutations not detectable by common molecular tests.
Antimicrob. Agents Chemother., 62, e00974–e00918.
Li,X. et al. (2018) Hyclasss: a hybrid classifier for automatic sleep stage scor-
ing. IEEE J. Biomed. Health Inform., 22, 375–385.
Malhi,A. and Gao,R.X. (2004) Pca-based feature selection scheme for
machine defect classification. IEEE Trans. Instrum. Meas., 53, 1517–1525.
Schleusener,V. et al. (2017) Mycobacterium tuberculosis resistance prediction
and lineage classification from genome sequencing: comparison of auto-
mated analysis tools. Sci. Rep. (Nat. Publisher Group), 7, 1–9.
Walker,T.M. et al. (2015) Whole-genome sequencing for prediction of
Mycobacterium tuberculosis drug susceptibility and resistance: a retrospect-
ive cohort study. Lancet Infect. Dis., 15, 1193–1202.
World Health Organization et al. (2016) Global Tuberculosis Report 2016.
World Health Organization.
Yang,Y. et al. (2018) Machine learning for classifying tuberculosis
drug-resistance from DNA sequencing data.Bioinformatics, 34, 1666–1671.
Zhang,H. et al. (2013) Genome sequencing of 161 Mycobacterium tubercu-
losis isolates from china identifies genes and intergenic regions associated
with drug resistance. Nat. Genet., 45, 1255–1260.
Zou,H. et al. (2006) Sparse principal component analysis. J. Comput. Graph.
Stat., 15, 265–286.










ollege London user on 30 January 2019
